4D Molecular Therapeutics, Inc. FDMT
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| Judah Frommer | Morgan Stanley | 5.52 $ | 6 $ | 0.48 % | 11/01/2025 |
| Kostas Biliouris | BMO Capital | 13.28 $ | 40 $ | 26.72 % | 19/09/2024 |
| Geulah Livshits | Loop Capital Markets | 13.3112 $ | 39 $ | 25.69 % | 19/09/2024 |
| Matthew Caufield | H.C. Wainwright | 13.3118 $ | 36 $ | 22.69 % | 19/09/2024 |
| Lisa Walter | RBC Capital | 26.35 $ | 40 $ | 13.65 % | 15/04/2024 |
| Gena Wang | Barclays | 26.35 $ | 45 $ | 18.65 % | 15/04/2024 |
| Nalin Tejavibulya | Jefferies | 31.86 $ | 58 $ | 26.14 % | 01/04/2024 |
| Kostas Biliouris | BMO Capital | 31.59 $ | 63 $ | 31.41 % | 28/03/2024 |
| Kostas Biliouris | BMO Capital | 30.705 $ | 70 $ | 39.30 % | 06/02/2024 |
| Geulah Livshits | Chardan Capital | 18.43 $ | 30 $ | 11.57 % | 05/07/2023 |
| Josh Schimmer | Evercore ISI | 14.66 $ | 40 $ | 25.34 % | 05/04/2022 |